HS
TRML

HighVista Strategies’s Tourmaline Bio TRML Stock Holding History

HighVista Strategies’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-83,397
Closed -$1.07M – 169
2024
Q2 		$1.07M Buy
83,397
+30,345
+57% +$488K 0.39% 100
2024
Q1 		$1.21M Buy
+53,052
New +$1.87M 0.43% 75

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

HighVista Strategies's TRML Position: Q3 2024 in Review

HighVista Strategies sold out of Tourmaline Bio (TRML) in Q3 2024, closing a stake of 83,397 shares — an estimated $1.07M sold.

HighVista Strategies first reported a position in TRML in Q1 2024 and held it in 2 quarters. The position peaked at $1.21M in Q1 2024. 92 funds tracked by Wall St. Rank hold TRML as of Q3 2024.

  • HighVista Strategies reported no remaining Tourmaline Bio position as of Q3 2024 after selling out during the quarter.
  • HighVista Strategies sold 83,397 Tourmaline Bio shares in Q3 2024, an estimated $1.07M.
  • HighVista Strategies first reported a position in Tourmaline Bio in Q1 2024 and held it in 2 quarters.
  • HighVista Strategies's Tourmaline Bio position peaked at $1.21M in Q1 2024.
  • 92 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2024.

Based on HighVista Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.